Company Overview and News


Add PODD
to your dashboard

Headline News

BRIEF-Insulet announces pricing of convertible senior notes due 2024

2017-11-08 reuters
* Insulet Corp - ‍priced a private placement of $350 million principal amount of convertible senior notes due 2024​

Biotech Forum Daily Digest: Why Adamas Is Soaring

2017-11-06 seekingalpha
Biotech had a nice rally on Friday, which allowed the main biotech indices to post a slight gain on the week. (138-1)

Your Daily Pharma Scoop: Progenics Looks Promising, Big Week For Dynavax, Keryx Ahead Of Catalyst

2017-11-06 seekingalpha
This abridged “Daily Scoop” is published by Avisol Capital Partners, which runs the physician-managed Total Pharma Tracker healthcare investment research service on Seeking Alpha Marketplace. (692-4)

Insulet (PODD) Q3 2017 Results - Earnings Call Transcript

2017-11-03 seekingalpha
Good afternoon, ladies and gentlemen, and welcome to the Insulet Corporation Third Quarter 2017 Earnings Call. At this time, all participants are in a listen-only mode. Later, we will conduct a question-and-answer session, and instructions will follow at that time. As a reminder, this conference call is being recorded. (0-1)

Insulet Corporation to Host Earnings Call

2017-11-02 accesswire
NEW YORK, NY / ACCESSWIRE / November 2, 2017 / Insulet Corporation (NASDAQ: PODD) will be discussing their earnings results in their Q3 Earnings Call to be held on November 2, 2017 at 4:30 PM Eastern Time. (3-1)

Insulet Offers Welcome Program For Animas Users To Try Omnipod Insulin Management System At Zero Cost

2017-10-07 devicespace
BILLERICA, Mass.--(BUSINESS WIRE)--Insulet Corporation’s (NASDAQ: PODD) (Insulet or the Company), the leader in tubeless insulin pump technology with its Omnipod® Insulin Management System (Omnipod System), is offering the Omnipod® Welcome Program for existing Animas® insulin pump users as part of the Company’s commitment to the diabetes community. This program provides users with a no cost trial of the Omnipod System.

Insulet To Announce Third Quarter 2017 Financial Results On November 2, 2017

2017-10-03 devicespace
BILLERICA, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the leader in tubeless insulin pump technology with its Omnipod® Insulin Management System, today announced plans to release its financial results for the third quarter of 2017 on November 2, 2017 after the close of the financial markets. In connection with the release, management will host a conference call that day at 4:30 p.

Rtw Investments, Llc - Current Holdings - Fintel.io

2017-09-28 fintel.io
Rtw Investments, Llc has disclosed 28 total holdings in their latest SEC filings. Most recent portfolio value is calculated to be $ 265,662,000 USD. Actual Assets Under Management (AUM) is this value plus cash (which is not disclosed). Rtw Investments, Llc's top holdings are Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) , PTC Therapeutics, Inc. (NASDAQ:PTCT) , AveXis, Inc. (NASDAQ:AVXS) , Bristol-Myers Squibb Co. (118-0)

Time To Buy Medtronic? Watch Diabetes Segment Transformation

2017-09-27 seekingalpha
Medtronic is confident of filling the supply-demand gap in its diabetes franchise by end of FY 2018. (64-1)

Medical Devices Are The Quiet Growth Sector

2017-09-21 seekingalpha
The medical device industry utilizes both low and advanced technology and often employs existing consumer products like smartphones. Thus, there is expanding utility and increasing demand for innovation. (163-1)

Earnings Review and Free Research Report: Hill-Rom’s Q3 Adjusted EPS Rose 12% Y-o-Y, Beating Expectations

2017-08-14 accesswire
LONDON, UK / ACCESSWIRE / August 14, 2017 / Pro-Trader Daily has just published a free post-earnings coverage on Hill-Rom Holdings, Inc. (NYSE: HRC), which can be viewed by registering at http://protraderdaily.com/optin/?symbol=HRC, following the Company's announcement of its financial results on July 28, 2017, for the third quarter fiscal 2017 (Q3 FY17). The Chicago, Illinois-based Company reported a 12% y-o-y growth in its adjusted diluted EPS, topping market consensus estimates.

Insulet (PODD) Shows Strength: Stock Adds 7.1% in Session

2017-08-07 zacks
Insulet Corporation (PODD - Free Report) was a big mover last session, as its shares rose over 7% on the day. The move came on the back of revenue growth and raised 2017 guidance in second-quarter 2017 results. This led to far more shares changing hands than in a normal session. This breaks the recent trend of the company, as the stock is now trading above the volatile price range $49.49 to $53.52 in the past one-month time frame.

Insulet Delivers 26% Revenue Growth and Raises 2017 Guidance; Stock Pumps Up 7%

2017-08-05 fool
Founded in 1993 by brothers Tom and David Gardner, The Motley Fool helps millions of people attain financial freedom through our website, podcasts, books, newspaper column, radio show, and premium investing services.

Healthcare Stock Performance Review -- Endologix, Zimmer Biomet, Insulet, and C.R. Bard

2017-08-04 prnewswire
If you want a Stock Review on ELGX, ZBH, PODD, or BCR then come over to http://dailystocktracker.com/register/ and sign up for your free customized report today. DailyStockTracker.com features the Healthcare sector, which includes health care providers and services, health care equipment and supplies, and health care technology companies. Equities under observation this morning are: Endologix Inc. (NASDAQ: ELGX), Zimmer Biomet Holdings Inc.

Insulet (PODD) Q2 2017 Results - Earnings Call Transcript

2017-08-04 seekingalpha
Good day, ladies and gentlemen, and welcome to the Q2 2017 Insulet Corporation Earnings Conference Call. At this time, all participants are in a listen-only mode. Later, we will conduct a question-and-answer session and instructions will follow at that time. As a reminder, this conference is being recorded.

CUSIP: 45784PAD3